Temporary Location Changes to 513 Union Meetings

Please note the changes for the April and June meetings. All meetings will start at their normal time, 7 pm. The location changes have been made to allow for social distancing. 

IUOE Supports Infrastructure NOW for IUOE Jobs

The bipartisan infrastructure framework agreed to by President Biden and a group of U.S. Senators is a down payment on world-class infrastructure that is safer, more reliable and will create good-paying jobs for Operating Engineers across the United States.

BIPARTISAN INFRASTRUCTURE FRAMEWORK:

  • Makes the single largest investment in roads and bridges since the construction of the interstate highway system, which will help us stay safe.
  • Delivers clean drinking water to American families by eliminating lead pipes.
  • Modernizes our power grid and makes it more resilient against cyber-attacks and extreme weather.
  • Delivers reliable high-speed internet access to American homes, drives down prices for internet services, and closes the digital divide.
  • Creates good-paying union jobs that will provide a pathway to the middle class for millions of American working families.

Connects prevailing wages and labor standards to the jobs created, helping to drive a strong and just economic recovery.

The bipartisan infrastructure framework is a blue-collar plan to invest in America by creating jobs for Operating Engineers and ensuring our communities have safe and resilient infrastructure.

Now we need Members of Congress to pass this legislation and create hundreds of thousands of good-paying construction jobs rebuilding our nation. Let’s get to work!

CALL YOUR SENATOR:  202-224-3121

EMAIL YOUR SENATOR NOW!

This Week in Labor History
513 Member Brittoni Calhoun Named Tradeswoman of the Year

BIG congrats to I.U.O.E. Local 513 Sister, Brittoni Calhoun on earning 2021 Tradeswomen of the Year! She will be honored at the Missouri Women in the Trades Blue Collar/Black Tie Award Gala. Would you like to attend the Gala? You can find out more information here

Election Commissioner Results

Election of Election Commissioners was held Friday, April 9th, 2021 at the St. Louis Union Hall per the Local 513 by-laws Article XV, Section 15.01.  The results are as follows:

Virgil Jeffery - 295

David Youngblood - 292

Mark Becker - 286

Chuck Margherio - 198

Mike Hart - 190

Steve Leslie - 199

Local 513 would like to thank the membership for participating in this process. 

Official Results for the August 10, 2021 Union Election

The official results are in for the August 10, 2021 Union Election.  Please click here to view the results.

 

This Week in Labor History
This Week in Labor History
This Week in Labor History
This Week in Labor History
Friendly reminder: Temporary Locations for Upcoming Union Meetings

Friendly reminder of our changed locations for our upcoming meetings. 

St. Louis Labor Council Cancels 2021 Labor Day Parade

St. Louis, MO - It is with great sadness and frustration that we are forced to cancel the 2021 St. Louis Labor Day Parade. This annual tradition has been a St. Louis staple for years to celebrate the working families and the strong labor roots of St. Louis. 

“We are canceling due to the COVID-19 pandemic and the growing concerns of the Delta Variant,” stated St. Louis Labor Council President Pat White. “This situation could have been avoided but much of our community continues to refuse to get vaccinated. Vaccinations work. Over 95% of those in our hospitals are unvaccinated and over 99% of the deaths due to COVID are those who are unvaccinated.” 

The 2021 Labor Day parade was set to be held on September 6, 2021 in downtown St. Louis. The Labor Day parade attracts dozens of labor unions, union members, their families and supporters each year. The parade takes many months to plan and organize. The 2020 parade was also cancelled due to the global pandemic. 

“I am encouraging those who have not been vaccinated against this pandemic both union members and non-union members to get their shot,” expressed Pat White. “This is something I look forward to each year. I am afraid that we are headed in the wrong direction and that if vaccination rates don’t increase we will see many more events in our community get canceled. Together we can beat this. This isn’t about politics, it is about science and loving thy neighbor. Protect yourself, your loved ones, and our community, get the damn vaccine.” 

Goodbye and Good Riddance

President Biden is living up to his pledge to fully support labor.  Please see the link below to read the article.

President Biden fires GC Peter Robb!

Postitive COVID-19 Test Result

IUOE Local 513 has been informed that a member who was in attendance at the union meeting on 8.13.21 has tested positive for COVID-19. Because of the union hall’s mask requirement and social distancing at the meeting members should only monitor themselves for symptoms, no other action is required. If you start to show symptoms please get tested.

Here is more information from the CDC on guidelines: https://bit.ly/3j8kR1T

20 Things Biden Has Done to Help Unions and Workers
FDA Approves First COVID-19 Vaccine

Please get the COVID-19 vaccine to protect you, your loved ones, your brothers, and your sisters!

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.” 

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval. 

Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. The result of a person receiving this vaccine is that their immune system will ultimately react defensively to the virus that causes COVID-19. The mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individual’s genetic material. Comirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart. 

“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. “We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S."

FDA Evaluation of Safety and Effectiveness Data for Approval for 16 Years of Age and Older

The first EUA, issued Dec. 11, for the Pfizer-BioNTech COVID-19 Vaccine for individuals 16 years of age and older was based on safety and effectiveness data from a randomized, controlled, blinded ongoing clinical trial of thousands of individuals. 

To support the FDA’s approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population. 

Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease. 

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.

Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.

Ongoing Safety Monitoring

The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.

The FDA granted this application Priority Review. The approval was granted to BioNTech Manufacturing GmbH.

Related Information

Support SB 262 for IUOE Jobs: Bipartisan Investment in Missouri Infrastructure!

Missouri’s infrastructure is crumbling. Our state is falling behind and putting our working families at risk. Missouri's transportation network directly impacts the quality of life for Missourians. Good roads and bridges connect us to work, school, healthcare, and recreation. Poor roads and bridges are a threat to the health and well-being of Missouri’s working families.

Senate Bill 262 is a bipartisan bill that aims to fix these problems. Despite maintaining the 7th largest transportation system in the United States, Missouri ranks 45th in transportation funding.

  • $825 million in high-priority transportation needs go unfunded every year.

  • Due to inflation and the ever-improving vehicle fuel economy, the purchasing power of Missouri’s state fuel tax has effectively dropped from 17 cents to 6 cents.

  • More than 6,700 miles of Missouri roadways are in poor condition.

  • Over 2,000 bridges in Missouri are rated as structurally deficient

By passing Senate Bill 262, we provide our state with the tools to fix these problems. And SB 262 will provide our state with good-paying UNION jobs for years and years to come. Those good-paying jobs with benefits will benefit Missouri workers and will build a stronger community and economy for all working families.

CALL your Senator and ask them to support the bipartisan Senate Bill 262 for good-paying jobs and investment in our aging infrastructure.

IUOE 513 Newsletters